{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-038728","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.680558+00:00","generated_at":"2026-05-24T21:27:43.035073+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IN8bio reports Q4 2024 net loss $6.2M; cash $11.1M as of Dec 31; clinical updates on INB-100/200/400","bullets":["Net loss Q4 2024 $6.2M ($0.08/share) vs $7.6M ($0.22/share) in Q4 2023; full-year net loss $30.4M vs $30.0M.","Cash $11.1M as of Dec 31, 2024; plus $4.1M net proceeds from ATM/warrant exercises in Feb 2025, extending runway into March 2026.","INB-100 Phase 1: 100% of treated AML patients relapse-free as of Jan 17, 2025; no CRS/ICANS; enrollment expansion ongoing.","INB-200: majority of patients exceeded expected PFS; one IDH-mutant patient progression-free for 40.5 months as of Oct 2024.","INB-400 Phase 2 enrollment paused; seeking partnerships; introduced INB-600 platform (INB-619 TCE targeting CD19) with preclinical data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-038728","json":"https://secwatch.observer/filing/0000950170-25-038728.json","markdown":"https://secwatch.observer/filing/0000950170-25-038728.md","text":"https://secwatch.observer/filing/0000950170-25-038728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000095017025038728/0000950170-25-038728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000095017025038728/inab-20250313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:27:43.035073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}